Harvard Bioscience (NASDAQ:HBIO) Rating Lowered to “Hold” at StoneX

Harvard Bioscience (NASDAQ:HBIO) was downgraded by StoneX from a “speculative buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Marketbeat.com reports.

HBIO has been the subject of several other research reports. Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Benchmark lifted their price target on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a report on Wednesday, August 12th. Finally, Zacks Research started coverage on shares of Harvard Bioscience in a report on Tuesday, November 3rd. They issued a “hold” rating for the company. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $6.75.

Harvard Bioscience Trading Down 4.8%

Shares of HBIO opened at $9.22 on Wednesday. Harvard Bioscience has a 52 week low of $4.00 and a 52 week high of $10.20. The company has a current ratio of 1.76, a quick ratio of 0.98 and a debt-to-equity ratio of 7.28. The stock has a 50 day moving average of $8.31 and a 200-day moving average of $6.57.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative return on equity of 43.94% and a negative net margin of 13.20%. The business had revenue of $22.20 million for the quarter, compared to analyst estimates of $21.80 million. As a group, sell-side analysts expect that Harvard Bioscience will post -2.44 EPS for the current year.

Institutional Trading of Harvard Bioscience

A hedge fund recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC bought a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned about 0.29% of Harvard Bioscience at the end of the most recent quarter. 80.87% of the stock is currently owned by institutional investors and hedge funds.

About Harvard Bioscience

Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.